In the top M&A, Merck entered into a definitive agreement to acquire privately held Eyebiotech for $1.3bn up front in cash and up to $1.7bn in developmental, regulatory and commercial milestone payments. EyeBio is developing candidates aimed at preventing and treating vision loss associated with retinal vascular leakage. Its lead candidate Restoret is a potential first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway. It demonstrated positive results in a Phase Ib/IIa trial in patients with diabetic macular edema and neovascular age-related macular degeneration. Financing reached $9bn in biopharma, $1.5m in device, and $678m in diagnostics.
Welcome to In Vivo
Create an account to read this article
Already a subscriber?